The 11th Annual New York Lung Cancer Symposium® is a 1-day educational and scientific meeting that will provide an update on state-of-the-art management of patients with lung cancer, as well as a focus on future therapies in development.
The past decade in lung cancer research has yielded a wealth of therapeutic options for patients with lung cancer, as well as greater knowledge of the many different subtypes of this disease. In particular, agents targeting oncogenic drivers and immunotherapeutic approaches have both transformed the management of patients with lung cancer in recent years. Furthermore, numerous investigational approaches are in late-phase evaluation, with the potential to change standards of care in 2016 and beyond. However, although these developments hold the promise to further improve outcomes for patients with lung cancer, they also raise challenges for busy clinicians to maintain state-of-the-art approaches in their practices.
This year’s program, led by world-class thoracic oncologists Mark G. Kris, MD, and Roman Perez-Soler, MD, will focus on a number of core areas that are key to optimizing care for patients with lung cancer, including targeted therapy, immunotherapy, adjuvant therapy, combined modality therapy, and approaches for challenging subtypes, such as squamous lung cancer. Participants will have an opportunity to learn from engaging presentations delivered by leading experts, as well as apply their knowledge in case-based panel discussions. This fast-paced, highly practical, and interactive forum will once again provide physicians who treat patients with lung cancer unique access to renowned international experts in the management of these tumors.
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High Cancers
Aug 29, 2018
Aug 31, 2018